DE69814133D1 - Zusammensetzung um die löslichkeit von igf-i zu erhöhen - Google Patents

Zusammensetzung um die löslichkeit von igf-i zu erhöhen

Info

Publication number
DE69814133D1
DE69814133D1 DE69814133T DE69814133T DE69814133D1 DE 69814133 D1 DE69814133 D1 DE 69814133D1 DE 69814133 T DE69814133 T DE 69814133T DE 69814133 T DE69814133 T DE 69814133T DE 69814133 D1 DE69814133 D1 DE 69814133D1
Authority
DE
Germany
Prior art keywords
igf
solubility
composition
increase
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69814133T
Other languages
English (en)
Other versions
DE69814133T2 (de
Inventor
A Shirley
Kamaljit Bajwa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of DE69814133D1 publication Critical patent/DE69814133D1/de
Publication of DE69814133T2 publication Critical patent/DE69814133T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE69814133T 1997-11-07 1998-11-06 Zusammensetzung um die löslichkeit von igf-i zu erhöhen Expired - Fee Related DE69814133T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6489197P 1997-11-07 1997-11-07
US64891P 1997-11-07
PCT/US1998/023673 WO1999024063A1 (en) 1997-11-07 1998-11-06 Compositions providing for increased igf-i solubility

Publications (2)

Publication Number Publication Date
DE69814133D1 true DE69814133D1 (de) 2003-06-12
DE69814133T2 DE69814133T2 (de) 2004-04-01

Family

ID=22058908

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69814133T Expired - Fee Related DE69814133T2 (de) 1997-11-07 1998-11-06 Zusammensetzung um die löslichkeit von igf-i zu erhöhen

Country Status (6)

Country Link
EP (1) EP1028748B1 (de)
JP (1) JP2001522814A (de)
AT (1) ATE238807T1 (de)
AU (1) AU1519399A (de)
DE (1) DE69814133T2 (de)
WO (1) WO1999024063A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2369451C (en) 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
MX2008009125A (es) * 2006-01-18 2008-10-23 Qps Llc Composiciones farmaceuticas con estabilidad mejorada.
EA202191513A1 (ru) * 2014-10-23 2021-11-30 Эмджен Инк. Снижение вязкости фармацевтических составов

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
SE9300105D0 (sv) * 1993-01-15 1993-01-15 Kabi Pharmacia Ab Stable protein solution

Also Published As

Publication number Publication date
EP1028748A1 (de) 2000-08-23
JP2001522814A (ja) 2001-11-20
AU1519399A (en) 1999-05-31
ATE238807T1 (de) 2003-05-15
WO1999024063A9 (en) 1999-08-12
WO1999024063A1 (en) 1999-05-20
DE69814133T2 (de) 2004-04-01
EP1028748B1 (de) 2003-05-02

Similar Documents

Publication Publication Date Title
BG103485A (en) Ketobanzamides as calpain inhibitors
DK0768997T3 (da) Polyalkoxyterpenderivater og sammensætninger indeholdende disse
IL117144A0 (en) Pharmaceutical compositions containing nucleic acids
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
CA2278201A1 (en) Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene, and processes for their preparation
DE69932645D1 (de) Neue Fettsäureanaloge zur Behandlung der Fettleber
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
PL313821A1 (en) Analogues of distamycin a as anticarcinogenic and antiviral agents
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
NZ279397A (en) Mercaptoacetylamido 1,3,4,5-tetrahydro-benzo[c]azepin-3-one disulfide derivatives and pharmaceutucal compositions
KR960700323A (ko) 냉매 조성물(refrigerant compositions)
PH30705A (en) Detergent composition comprising an alkyl sulphateand a subtilisin variant.
HK1028568A1 (en) Alpha-ketoamide multicatalytic protease inhibitors
WO1987004426A3 (fr) Compositions de vinyle
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
EP0885880A3 (de) Sulfonylalkanoylaminohydroxyethylaminosulfamidsäuren verwendbar als retrovirale Proteasehemmer
IT1293778B1 (it) 1,4,7,10-tetraazabiciclo(8.2.2.)tetradecan-2 one, sua preparazione e suo uso per la preparazione di tetraazamacrocicli
ES2131528T3 (es) Nuevos polipeptidos y su uso.
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
IT8567393A0 (it) Derivati di delta 2-1,2,4-triazolin5-one e composizioni erbicide cheli contengono
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
MY122086A (en) Liquid crystal compositions
ATE238807T1 (de) Zusammensetzung um die löslichkeit von igf-i zu erhöhen
MX9706958A (es) Composiciones refrigerantes.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS,INC.(N.D.GES, US

8339 Ceased/non-payment of the annual fee